NCT07028008
Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte in Patients With Refractory Melanoma Who Failed to Immune Checkpoint Inhibitors
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 2 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Eligibility criteria expanded, about 38 words
- Study sites: 0 to 1
- Start date changed from estimate of Oct 15, 2025 to Jul 2, 2025
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Safety evaluation
Timeframe: up to 6 months after TIL administration
Secondary (5)
Overall Response Rate
Duration of Response
Disease Control Rate
Progression Free Survival
Overall Survival
Arms and interventions
tumor-infiltrating lymphocyte (TIL) therapyExperimental
1\~100 x 10 9 cells, 1time, IV
Biologicals: tumor-infiltrating lymphocyte (TIL)
Sites
1 site in 1 country
- Samsung Medical CenterSeoul, Gang-Nam, South Korea